Adding a DPP-4 inhibitor to metformin therapy may be safer than you think

References

• International Diabetes Federation, 2012 Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Available at: http://www.idf.org/sites/default/files/IDF%20T2DM%20Guideline.pdf [Last accessed 27 November 2013]
   Google Scholar
• Garber AJ. Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care 2011;34:S258-63
   PubMed Web of Science ®Google Scholar
• Gleason CE, Gonzalez M, Harmon JS, et al. Determinants of glucose toxicity and its reversibility in the pancreatic islet β-cell line, HIT-T15. Am J Physiol Endocrinol Metabol 2000;279:E997-1002
   PubMed Web of Science ®Google Scholar
• Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract Suppl 2007;61(s153):20-7
   Google Scholar
• Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Bakatselos SO. Hypoglycemia unawareness. Diabetes Res Clin Pract 2011;93(Suppl 1):S92-6
   PubMedGoogle Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33:1389-94
   PubMed Web of Science ®Google Scholar
• Fanelli CG, Pampanelli S, Porcellati F. Cognitive function in hypoglycaemia. Diabetes Nutr Metabol 2002;15:367-72
   PubMedGoogle Scholar
• Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009;32:1513-17
   PubMed Web of Science ®Google Scholar
• Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:405-14
   PubMed Web of Science ®Google Scholar
• van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41
   PubMed Web of Science ®Google Scholar
• Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1121-7
   PubMed Web of Science ®Google Scholar
• Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 2005;16(Suppl 1):S7-10
   PubMedGoogle Scholar
• Veitch PC, Clifton-Bligh RJ. Long-acting sulfonylureas – long-acting hypoglycaemia. Med J Aust 2004;180:84-5
   PubMed Web of Science ®Google Scholar
• Marques JL, George E, Peacey SR, et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diab Med 1997;14:648-54
   PubMed Web of Science ®Google Scholar
• Landstedt-Hallin L, Englund A, Adamson U, et al. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999;246:299-307
   PubMed Web of Science ®Google Scholar
• Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011;34(Suppl 2):S132-7
   PubMed Web of Science ®Google Scholar
• Bron M, Marynchenko M, Yang H, et al. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012;124:124-32
   PubMed Web of Science ®Google Scholar
• Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998;21(Suppl 3):C35-8
   PubMedGoogle Scholar
• Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369
   PubMed Web of Science ®Google Scholar
• Group UKPDS. U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8
   PubMed Web of Science ®Google Scholar
• Hernandez AV, Usmani A, Rajamanickam A, et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011;11:115-28
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5
   PubMed Web of Science ®Google Scholar
• Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Can Med Assoc J 2012;184:E675-83
   PubMed Web of Science ®Google Scholar
• Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80
   PubMed Web of Science ®Google Scholar
• Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
   PubMed Web of Science ®Google Scholar
• Karasik ACB, Liu J, Wu M, et al. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Poster 501-P presented at the American Diabetes Association 66th Annual Meeting and Scientific Sessions in Washington DC, June 2006
   Google Scholar
• Rosenstock JBR, Andryuk PJ, Lu K, et al. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM). Poster 556-P presented at the American Diabetes Association 66th Annual Meeting and Scientific Sessions in Washington DC, June 2006
   Google Scholar
• Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metabol 2009;11:157-66
   PubMed Web of Science ®Google Scholar
• Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 Countries: Results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11
   PubMed Web of Science ®Google Scholar
• Aravind SR, Al Tayeb K, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin 2011;27:1237-42
   PubMed Web of Science ®Google Scholar
• Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin 2012;28:1289-96
   PubMed Web of Science ®Google Scholar
• Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 2013;67:947-56
   PubMed Web of Science ®Google Scholar
• Göke R, Gruenberger JB, Bader G, Dworak M. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany. Curr Med Res Opin 2014;30:785-9
   Google Scholar
• Bluher M, Kurz I, Dannenmaier S, et al. Efficacy and safety of vildagliptin in clinical practice – results of the PROVIL-study. World J Diabetes 2012;3:161-9
   PubMedGoogle Scholar